Over the last 17years, clinical trials conducted worldwide have demonstrated the efficacy of
arsenic trioxide (As2O3) in the treatment of relapsed acute promyelocytic leukemia (APL) …

The platinum antitumor drugs cisplatin, carboplatin and oxaliplatin are widely used
components of modern cancer chemotherapy. However, their success is limited by severe …

Mineral arsenicals have long been used in traditional medicines for various diseases, yet
arsenic can be highly toxic and carcinogenic. Arsenic in traditional medicines typically …

Arsenic trioxide (ATO) is presently the most active single agent in the treatment of acute
promyelocytic leukemia (APL). This review provides insights into the mode of action and the …

The aim of our study was to construct an Arg-Gly-Asp (RGD)-conjugated liposome-hollow
silica hybrid nanovehicle for targeted delivery and controlled release of arsenic trioxide …

Differentiation Syndrome (DS) has been identified in a subset of patients undergoing
treatment with novel classes of differentiating therapies for acute myeloid leukemia (AML) …

Arsenic trioxide (As2O3, ATO), a FDA approved drug for hematologic malignancies, was
proved of efficient growth inhibition of cancer cell in vitro or solid tumor in vivo. However, its …

Inorganic arsenic (iAs) is a complete transplacental carcinogen in mice. Previous studies
have demonstrated that in utero exposure to iAs promotes cancer in adult mouse offspring …

Method development and applications of hyphenated techniques as tools for speciation
analysis of metal-based pharmaceuticals are summarized within this review. Advantages …

The therapeutic potential of arsenic derivatives has long been recognized and was recently
rediscovered in modern literature. Early studies demonstrated impressive activity of this …